Most importantly, they indicated that FGFR3 inhibition potentially remolds the immune contexture of UTUC and provides a rationale for combined treatment with PD‐1/PD‐L1 and an FGFR3 inhibitor.30 Here, FGFR3 is linked to renal pelvis/ureter urothelial carcinoma.